Detalhe da pesquisa
1.
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.
Cell
; 159(1): 80-93, 2014 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25259922
2.
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
Br J Cancer
; 129(2): 309-317, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237172
3.
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
Ann Surg Oncol
; 30(2): 1099-1109, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36305992
4.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919668
5.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724226
6.
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Oncologist
; 27(9): 716-e689, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552447
7.
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Invest New Drugs
; 40(6): 1306-1314, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264382
8.
Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma.
Proc Natl Acad Sci U S A
; 116(52): 26835-26845, 2019 Dec 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843922
9.
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report.
Cancer
; 126(23): 5022-5029, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970346
10.
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Br J Cancer
; 122(3): 333-339, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31787751
11.
Early treatment-related neutropenia predicts response to palbociclib.
Br J Cancer
; 123(6): 912-918, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641862
12.
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Br J Cancer
; 122(4): 498-505, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857726
13.
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.
Oncologist
; 25(12): e1864-e1868, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32692450
14.
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).
Oncologist
; 25(5): e798-e807, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31852811
15.
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Cancer
; 124(4): 688-697, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29211295
16.
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Cancer
; 121(9): 1463-8, 2015 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25522918
17.
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.
Oncologist
; 20(8): 952-9, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26084808
18.
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Cancer
; 120(1): 77-85, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24108668
19.
Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
J Natl Cancer Inst
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775718
20.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
JCO Precis Oncol
; 8: e2300407, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603650